Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BEBT 908

Next Previous
X
Search
Drug Profile

BEBT 908

Alternative Names: BEBT-908; CUDC-908

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou BeBetter Medicine Technology
  • Developer BeBetter Med
  • Class Antineoplastics; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Ferroptosis stimulants; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy, Second-line therapy or greater) in China (IV, Infusion)
  • 18 Oct 2023 Phase-III clinical trials in Diffuse large B cell lymphoma (Recurrent, Second-line therapy or greater) in China (IV) prior to October 2023 (BeBetter Med pipeline, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top